Science and Research

Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers. (AMIR-21)

The goal of this clinical trial is to evaluate the safety and tolerability of RCS-21 in healthy volunteers. Participants will be asked to inhale a single or multiple doses of RCS-21 for a maximum of 7 days and their health status will be constantly monitored.

Study details
Study-ID: NCT06752122, 2024-512351-21-00
Study-ID: NCT06752122, 2024-512351-21-00
DZL Disease Area: COPD, PALI
DZL Disease Area: COPD, PALI
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center, DZL Investigator Initiated Trial, DZL on steering board
DZL Role: DZL recruiting center, DZL Investigator Initiated Trial, DZL on steering board
Funding: Externally - industry, Externally - public
Funding: Externally - industry, Externally - public
DZL Participating Sites: ARCN, BREATH
DZL Participating Sites: ARCN, BREATH
Start Date: 18.02.2025
Completion Date: 31.03.2026
Status: Recruiting
Status: Recruiting
DZL recruiting center, DZL Investigator Initiated Trial, DZL on steering board
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.